disease severity

BIOLOGICAL2 trials

Sponsors

University of Ulster, Drug Target ID, Ltd.

Conditions

COVID-19demyelinating disease multiple sclerosis

Unknown Phase

Study on the relationship between genes and disease severity, disease burden and effectiveness of disease modifying medication in Dutch patients with Multiple Sclerosis

Active, not recruitingNL-OMON45439

Drug Target ID, Ltd.demyelinating disease multiple sclerosis

Start: 2017-03-01Target: 600Updated: 2024-02-28

COVID RESPONSE STUDY (COVRES)

CompletedNCT05548829

University of UlsterCOVID-19

Start: 2020-12-01End: 2022-04-29Updated: 2022-09-21

Related Papers

Longitudinal sequelae of COVID-19 hospitalisation 3–12 months post Omicron infection

Scientific Reports2026-08-27